Abbott Laboratories (ABT) earnings call transcript summary & sentiment

Our read on the 16 July 2026 earnings call

Overall tone

Positive

Executive Summary

Abbott Laboratories delivered second-quarter comparable sales growth of 4.8% and adjusted EPS of $1.31, beating the midpoint of guidance and consensus expectations.

Core Signals

Revenue Growth & Demand: Comparable sales grew 4.8% in the quarter with sequential acceleration across each month, supported by stable diagnostic volume demand.

Bullish Signals

Full-year adjusted EPS guidance was raised to $5.45–$5.60 based on strong execution and sustained gross margin expansion.

Risk Signals

Continuous glucose monitoring growth decelerated to 9.5%, with near-term re-acceleration heavily dependent on unpredictable reimbursement timing.

Q&A Signals

Repeated analyst topics: Analysts repeatedly questioned second-half revenue acceleration drivers, Libre CGM growth trajectory, structural heart fixes, and long-term 2027 growth expectations.

Key Investor Debate

The primary debate centers on whether Abbott can successfully achieve its required second-half revenue acceleration to hit the 6.5%–7.5% full-year organic growth target amid moderated CGM growth (9.5%) and U.S. Structural Heart softness.

Analyst Takeaway

Management's commentary provides high credibility around profitability gains and pipeline execution, effectively using Q&A to de-risk macro worries regarding U.S. healthcare utilization.